Company intelligence / Profile preview

ACOME

Vancouver, British Columbia, Canadaacome.com ↗

Ownership: Private
Development stage: Commercial

Overview

Akome developed proprietary drug formulations that combine psychedelics with plant bioactives to target neurological disorders. Four provisional composition patents were filed for DMT-, psilocybin-, and ketamine-based combinations targeting Parkinson’s, ischemic stroke, Alzheimer’s, and depression. No clinical results reported as of the 2021 acquisition by Core One Labs.

Therapeutic areas: PsychiatryCardiovascularNeurology
Modalities: Small molecule (psychedelic compounds)Plant bioactive-based drugsCombination therapies (psychedelics + plant bioactives)
Industry: Biotech

Partnerships

None publicly disclosed as of acquisition date.

Beyond the preview

Go deeper on ACOME.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACOME.

Explore the full profile